Cystic fibrosis (CF) is one of the most common recessive genetic diseases, with a wide spectrum of phenotypes, ranging from infertility to severe pulmonary disease. Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene are considered the main genetic cause for CF. In this study, we recruited a consanguineous Iranian pedigree with four male patients diagnosed with congenital unilateral absence of the vas deferens (CUAVD), and one female patient diagnosed with congenital absence of the uterus (CAU). Testicular biopsy of one patient was performed, and hematoxylin and eosin (H and E) staining of testis sections displayed the presence of germ cell types ranging from spermatogonia to mature spermatids, indicating obstructive azoospermia. To explore the underlying genetic factor in this familial disorder, we therefore performed whole-exome sequencing (WES) on all available family members. WES data filtration and CFTR haplotype analysis identified compound heterozygous mutations in CFTR among four patients (two CUAVD patients carried p.H949Y and p.L997F, and one CUAVD and the female CAU patient carried p.H949Y and p.I148T). All these mutations were predicted to be deleterious by at least half of the prediction software programs and were confirmed by Sanger sequencing. Our study reported that CFTR compound heterozygous mutations in a consanguineous Iranian family cause infertility in both sexes.

Keywords: congenital absence of the uterus; congenital unilateral absence of the vas deferens; cystic fibrosis transmembrane conductance regulator; whole-exome sequencing

INTRODUCTION

Infertility is described as the inability to achieve pregnancy after 12 months of regular unprotected sexual intercourse, and about 15% of couples are affected worldwide. Reproductive failure is linked to several genetic defects, typically chromosomal anomalies and gene mutations. Male factors contribute to around 50% of infertility cases, while 10%–15% of fertile men suffer from azoospermia. Still, the major etiology of male infertility remains largely unknown.

Cystic fibrosis (CF) disorder is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is located on chromosome 7q31, contains 27 exons, and spans about 190 kb at the genomic level. It encodes a transmembrane chloride (Cl−) channel that has anion transport and fluid reabsorption function. The CFTR protein is a glycosylated transmembrane protein, consisting of two transmembrane domains (TMD1 and TMD2), two nucleotide binding domains (NBD1 and NBD2), and a regulatory (R) domain that is expressed in the epithelial cells of exocrine tissues including lungs, pancreas, sweat glands, and vas deferens. So far, more than 2000 variants that lead to impairment in chloride transport in most of the exocrine glands, resulting in abnormally thick mucus secretion, have been identified in the CFTR gene (https://www.cftr2.org/). Patients with classical CF characteristics usually have bi-allelic CFTR variants and suffer from lung problems and pancreatic insufficiency. However, mild diseases such as congenital absence of the vas deferens (CAVD) without other typical clinical manifestations of CF may result from the variation in alternative mRNA splicing or different sensitivity levels to dysfunctional CFTR protein among various organs. The mutation spectrums of typical CF and CAVD are thus diversified. Approximately 95% of males with CF have primary infertility with obstructive azoospermia (OA), and CFTR variants are the main
genetic cause of CAVD/CUAVD and congenital bilateral absence of the vas deferens (CBAVD).\textsuperscript{20,21} CBAVD is the most common subtype with 1%–2% prevalence but can go up to 25% in OA cases, while the incidence of CUAVD is 0.5%–1.0% and usually recognized during evaluations for infertility.\textsuperscript{22,23} According to previous reports, most CAVD patients have a compound heterozygous genotype with mutations in different alleles, and around 43% of CUAVD patients carry at least one \textit{CFTR} variant.\textsuperscript{24,25}

Congenital absence of uterus and/or vagina (CAUV/CAU), which affects 1 in 5000 women, is associated with \textit{CFTR} mutations. The frequency of the most common mutations of \textit{CFTR} in patients with CAU was 8%, twice the incidence of that in the general population (4%).\textsuperscript{20,27} \textit{CFTR} variation thus rarely causes CAU, with a few sporadic cases reported so far.

In this study, we recruited a consanguineous Iranian family, in which male patients were suffering from CUAVD and one female patient was diagnosed with CAU. Whole-exome sequencing (WES) was performed to determine the genetic cause of CUAVD and CAU, and \textit{CFTR} compound heterozygous mutations were identified in four patients.

**Materials and Methods**

**Family recruitment**

An Iranian family comprising four infertile brothers and one infertile sister (IV:2, IV:7, IV:9, IV:13, and IV:5), who are offspring of a first-degree consanguineous marriage, were recruited from the affiliated Armaghan Clinic of Mashhad University of Medical Sciences, Mashhad, Iran (November, 2019). The infertile individuals were diagnosed by a panel of urologists and gynecologists, and the accessible clinical records and peripheral blood samples of all the available siblings and parents were collected. Furthermore, genomic DNA was extracted from blood using the FlexiGene DNA Kit (QIAGEN, Hilden, Germany) following the standard protocol. All the studies on patients were conducted after obtaining informed consent, and this project was approved by the ethical committee of University of Science and Technology of China (USTC; approval number: USTCEC202000003) and the Mashhad University of Medical Science (MUMS; approval number: MUMSEC130010405).

**Testicular biopsy and hematoxylin and eosin (H and E) staining**

Testicular biopsy is a significant component of male infertility workup to distinguish between obstructive and nonobstructive azoospermia. Open surgical biopsy is known as the gold standard for obtaining tissues and inspection of spermatogenesis.\textsuperscript{28} A small tissue sample was taken from both left and right testes of patient IV:13, and the samples were perfused overnight in Bouin’s fixative solution. Tissue embedding was then performed in paraflin to make blocks. Tissue sectioning was prepared by microtome, and H and E staining was subsequently carried out as described previously.\textsuperscript{29} A digital Nikon DS-Ri1 camera installed on a Nikon Eclipse 80i microscope (Nikon, Tokyo, Japan) was used to capture the images.

**WES and Sanger sequencing**

For exome capturing, an ALExome Enrichment Kit V1 (iGeneTech, Beijing, China) was used. Captured libraries were constructed for all the recruited family members, as per manufacturer’s instructions. Sequencing was carried out using the Novaseq 6000 platform (Illumina, San Diego, CA, USA). Raw data and WES data filtration were processed as described previously.\textsuperscript{30} \textit{CFTR} compound heterozygous mutations were confirmed by Sanger sequencing using the primers listed in Supplementary Table 1.

**In silico analysis**

The conservation of affected amino acids resulting from \textit{CFTR} mutations was predicted using MEGA6.\textsuperscript{31} The pathogenicity of these mutations was assessed via seven deleterious effects prediction software programs (Supplementary Table 2).

**Results**

**Family description**

The phenotypes of all the infertile individuals were recognized at Armaghan Clinic where they consulted for infertility treatment (Figure 1). Basic clinical parameters of all the CUAVD patients are summarized in Table 1. All the male patients including IV:13 displayed inherited lack of left vas deferens. The female with CAU (IV:5) was 36 years old with no cycle, and ultrasound test verified congenital lack of the uterus. The mother (III:2) experienced an irregular cycle and two miscarriages. Histochemical analysis indicated that IV:13 had standard testicular tissue with seminiferous tubules containing normal spermatogenesis composed of spermatogonia, spermatocytes, spermatids, and spermatozoa, consistent with a score of 9 on the Johnsen scale\textsuperscript{32} (Figure 2) and suggesting OA.

**CFTR variants identified in the patients**

Analysis of WES results showed no candidate mutations that were compatible with autosomal recessive inheritance regarding patients’ parents being first cousins. Considering that \textit{CFTR} is a major genetic factor for this type of disease, we retrieved all \textit{CFTR} variations identified by WES.

Two different compound heterozygous mutations of \textit{CFTR} were identified in four patients. Two male CUAVD patients, IV:7 and IV:2, shared \textit{CFTR} compound heterozygous mutations (ENST0000003084, p.H949Y and p.L997F); male CUAVD patient IV:13 and female CAU patient IV:5 carried \textit{CFTR} compound heterozygous mutations (ENST0000003084, p.H949Y and p.I148T). Sanger sequencing of these \textit{CFTR} mutations was performed, which further confirmed infertility phenotype co-segregated with \textit{CFTR} compound heterozygous mutations in the pedigree (Figure 3).\textsuperscript{33}

The c.443T>C (rs35516286) variant gives rise to isoleucine being replaced by threonine at position 148 in the \textit{CFTR} protein. The c.2845C>T (rs35516286) and the c.2991G>C (rs1800111) variants cause alteration of histidine to tyrosine at amino acid 949 and leucine transfer to phenylalanine at position 997 in the \textit{CFTR} protein, respectively (Supplementary Figure 1). All the detected variations localized in the transmembrane domain constructed from six membrane-spanning segments, each mediating the regulation of anion (Cl\textsuperscript{−}) transport across the apical membrane of epithelial cells.\textsuperscript{34} Each of these \textit{CFTR} compound heterozygous mutations had a rare allele frequency in the ClinVar public population database (Supplementary Table 3).\textsuperscript{35–37} \textit{CFTR} p.H949Y (rs121909035) has already been evaluated as “pathogenic” in ClinVar, while recent studies also showed that p.L997F (rs1800111) and p.I148T (rs35516286) are pathogenic and updated in ClinVar. Further, seven deleterious effects prediction software programs were used to predict the pathogenesis of \textit{CFTR} mutations, and they were predicted to be deleterious by more than half in silico programs (Supplementary Table 2). Further, all the identified mutations were mostly conserved in the eutherian species (Supplementary Figure 2).

**Discussion**

CF is a recessive genetic disease, with most cases caused by pathogenic mutations in \textit{CFTR}. Although CF is more frequent in the Caucasian population, it affects all ethnic groups, with particular variations (e.g., p.Phe508del) found in 90% of Caucasian patients.\textsuperscript{40–42} While the limited
knowledge on CF frequency and the spectrum of CFTR mutations among Iranians is probably due to misdiagnosis or lack of studies, previous research has reported that the prevalence of CF in Iran is approximately 1 in 100,000 cases, with DF508, N1303K, G542X, R347H, and W1282X being the most common mutations.\textsuperscript{43–45} The CFTR gene is located on the short arm of chromosome 7 (7q31), contains 27 exons, and spans about 190 kb,\textsuperscript{9,10} which encodes a transmembrane chloride (Cl\textsuperscript{−}) channel. This protein consists of two transmembrane domains, two nucleotide binding domains, and a regulatory domain that manages anion transport and fluid reabsorption function.

Almost all CF males have infertility resulting from OA, and CAVD is known as an atypical form of CF, but CAVD can occur without any typical manifestations of CF.\textsuperscript{46} A possible reason for this event could be the difference in alternative mRNA splicing between various organs, just as previous studies showed that mRNA splicing was more efficient in the respiratory epithelial than that in the vas deferens epithelial. Furthermore, the reproductive system is more sensitive to CFTR protein dysfunction than other tissues.\textsuperscript{46,47} Congenital absence of the vas deferens could be unilateral (CUAVD) as a result of mild CFTR mutation, with an incidence of 0.5%–1% in the male population and mostly double prevalence on the left compared with the right side.\textsuperscript{48,49} Based on Casals et al.\textsuperscript{40}’s report, 38% of the CUAVD cases correlate with mutations in the CFTR gene.

Although women with CF have thicker cervical mucus and ovulation issues, most affected females are fertile. According to a study by Timmreck et al.,\textsuperscript{25} CAU is a rare phenotype among women with CFTR mutations, and the majority of patients with CAUV/CAU do not carry CFTR mutations.

In the current study, we presented a consanguineous Iranian family suffering from infertility in both sexes, and for which, so far, there is no report of CF pedigree showing only infertility phenotype in both sexes. Further clinical study showed CUAVD in the male patients and CAU in the female patient. To investigate further, we examined gonadal hormone levels in serum, seminal volume and pH, and testicular size, which revealed normal results. Subsequently, spermatogenesis histochemical evaluation showed a standard sperm production procedure. This acquired information indicated OA. Herein, we performed WES of all the available family members’ gDNA to determine the role of genetic factors in this familial disorder. We found that male CUAVD patients IV:7 and IV:2 shared CFTR compound heterozygous mutations (ENST0000003084, p.H949Y and p.L997F), while male CUAVD patient IV:13 and female CAU patient IV:5 carried CFTR compound heterozygous mutations (ENST0000003084, p.H949Y and p.I148T). The identified mutations are located in transmembrane domains that mediate the regulation of anion (Cl\textsuperscript{−}) transport across the apical membrane of epithelial cells. p.H949Y was found in all infertile patients, except IV:9, whose gDNA sample was not available. We assumed he would show a compound heterozygous

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure1.png}
\caption{Pedigree structure of the family. IV:7 has an 11-year-old son but failed to conceive later. Physical examination and semen analysis showed lack of left vas deferens and azoospermia, suggesting secondary infertility. V:1 was born through a surrogate mother using IV:11 uteruses for transferring and developing zygotes of IV:5 and IV:6 by the IVF method. IVF: in-vitro fertilization; WES: whole-exome sequencing.}
\end{figure}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure2.png}
\caption{Normal distribution of germ cells and spermatogenesis. H and E staining of testes from normal individual (a) image captured on 20× and (b) image captured on 40× displaying normal spermatogenesis. H and E staining of the patient IV:13: (c) representative image captured on 20× and (d) representative image captured on 40× also displaying normal spermatogenesis indicating obstructive azoospermia. Scale bars = 100 µm. H and E: hematoxylin and eosin.}
\end{figure}
Mutations in CFTR cause CUAVD and CAU
MD Ghouchanatigh et al

State. This mutation is recorded in ClinVar as "pathogenic," and although mutations in another CFTR allele were different in these patients, our results provide solid evidence that the pathogenicity of CFTR p.H949Y is in an autosomal recessive pattern. All these CFTR mutations (p.I148T, p.H949Y, and p.L997F) were predicted to be disease causative by more than half of the deleterious prediction software programs. Previous studies have reported some bi-allelic variants of CFTR in some unrelated patients. Our study, in which CFTR compound heterozygous mutations were co-segregated with infertility phenotype in a large family, provides the first-known familial evidence that only recessive variants (homozygous or compound heterozygous) cause CUAVD/CAU.

CONCLUSION
In conclusion, we identified CFTR mutations in a consanguineous Iranian pedigree comprising several infertile offspring in both sexes. CFTR p.H949Y was found in both CUAVD and CAU patients, indicating that it played a critical role in the synergistic pathogenesis.

Table 1: Clinical parameters of congenital unilateral absence of the vas deferens patients

| Clinical parameter                  | IV:2 | IV:9 | IV:13 | IV:7 | Reference value (men), range |
|------------------------------------|------|------|-------|------|-------------------------------|
| Age (year)                         | 41   | 34   | 26    | 35   | NI                            |
| Height (cm)                        | 165  | 180  | 178   | 178  | NI                            |
| Weight (kg)                        | 90   | 87   | 78    | 70   | NI                            |
| BMI (kg m⁻²)                       | 33.1 | 26.9 | 24.6  | 22.1 | NI                            |
| Physical examination               |      |      |       |      |                               |
| Sperm concentration \(\times 10^6\) ml⁻¹ | 0    | 0    | 0     | 0    | >15                           |
| Semen volume (ml)                  | 2.0  | 2.5  | 2.1   | 2.9  | >1.5                          |
| pH                                 | 7.5  | 7.9  | 7.4   | 8.0  | 7.2–8.0                       |
| FSH (IU ml⁻¹)                      | 6.3  | 10.0 | 7.5   | 11.7 | 1.3–19.3                      |
| LH (IU l⁻¹)                        | 8.1  | 6.4  | 7.9   | 5.0  | 1.9–9.0                       |
| Testosterone (ng dl⁻¹)             | 358  | 730  | 571   | 607  | 200–800                       |

Ni: not included; FSH: follicle-stimulating hormone; LH: luteinizing hormone; BMI: body mass index

Figure 3: Validation of CFTR variants among family members by Sanger sequencing. (a) Chromatogram of CFTR variations showing the father and four patients (III:1, IV:2, IV:5, IV:7, and IV:13) were heterozygous (indicated by red arrows) for rs121990305 mutation, while the mother and normal sister (III:2 and IV:11) carried normal alleles (black arrows). (b) In rs35516286 variant, the father and two patients (III:1, IV:2, and IV:7) were normal, and the other participants carried heterozygous variation. (c) In the case of rs1800111, the mother and two patients (III:2, IV:2, and IV:7) carried heterozygous allele, while the father and the other offspring (III:1, IV:5, and IV:13) were normal. Ref: reference; A: adenine; C: cytosine; G: guanine; T: thymine; CFTR: cystic fibrosis transmembrane conductance regulator; mut: mutant; het: heterozygous. IV:9 patient’s DNA is not available, we assumed he would be in compound heterozygous state.
Acknowledgments

This work was supported by the National Key Research and Development Program of China (No. 2018YFC1003403 and No. 2018YFC1004700) and the National Natural Science Foundation of China (No. 32070850 and No. 2018YFC1003403 and No. 2018YFC1004700) and the Program of China (No. 2018YFC1003403 and No. 2018YFC1004700) and has been performed in the University of Lille, Faculty of Medicine, School of Medicine, INSERM, U1239, Lille, France.

This work was supported by the National Key Research and Development Program of China (No. 2018YFC1003403 and No. 2018YFC1004700) and the National Natural Science Foundation of China (No. 32070850 and No. 2018YFC1003403 and No. 2018YFC1004700) and the Program of China (No. 2018YFC1003403 and No. 2018YFC1004700) and has been performed in the University of Lille, Faculty of Medicine, School of Medicine, INSERM, U1239, Lille, France.
Mutations in CFTR cause CUAVD and CAU
MD Ghouchanatigh et al

47 Mo B, Garla V, Wyner LM. A case of congenital unilateral absence of the vas deferens. In Med Case Rep J 2013; 6: 21.
48 Weiske WH, Sälzler N, Schroeder-Printzen I, Weidner W. Clinical findings in congenital absence of the vasa deferentia. Andrologia 2000; 32: 13–8.
49 Kolettis PN, Sandlow JI. Clinical and genetic features of patients with congenital unilateral absence of the vas deferens. Urology 2002; 60: 1073–6.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. ©The Author(s)(2021)
Supplementary Figure 1: Identification and prediction effect of the CFTR variants. (A) The rs35516286 mutation take place in exon 4 which T altered to C at gDNA position 70 285 nucleoide (nt). In transcript mRNA, the mutated site is present at 443 nt. The CFTR protein comprises of transmembrane domain, nucleotide binding domain, and R- domain. In mutant protein, I replace with T at amino acid 148 which lies in transmembrane domain. (B) The rs121909035 variation arise in exon 17 leads to alteration of C to T at gDNA position 142 936 bp, and 2845 nt in cDNA resulting in replacement of H with Y at amino acid 949 in protein. This mutation placed in transmembrane domain. (C) The rs1800111 variant occurs in exon 19 and in this variant G replaced with C at position 149 738 nt in gDNA and 2991 nt in cDNA. Following this mutation, L exchange with F at amino acid 997 which lies in transmembrane domain. Pink arrow heads indicate mutation sites and the altered amino acid.
Supplementary Figure 2: The conservation of affected amino acids. Sequence alignment using MEGA6 predicted the conservation of isoleucine (a), histidine (b), and leucine (c) amino acids.
### Supplementary Table 1: Primers used for Sanger sequencing

| CFTR variants | Forward primer | Reverse primer | Size (bp) |
|---------------|----------------|----------------|-----------|
| rs121909035   | 5'-AGTAAGTAACTTTGGCTGCC-3' | 5'-CAGTCAAATGAGGTTCAAC-3' | 431       |
| rs1800111     | 5'-ACCTAATGCTAGTAGACAGA-3' | 5'-TTAAAGATGTATCGACAC-3' | 428       |
| rs35516286    | 5'-TTGTAGGAGTCACCAAGC-3' | 5'-GAGCAATTATTATCTGCAC-3' | 377       |

CFTR: cystic fibrosis transmembrane conductance regulator

---

### Supplementary Table 2: Prediction pathogenicity of mutations by several software

| Prediction method             | p.I148T             | p.H949Y             | p.L997F             |
|------------------------------|---------------------|---------------------|---------------------|
| SIFT                         | Tolerated           | Deleterious         | Tolerated           |
| Polyphen2                    | Benign              | Probably damaging   | Probably damaging   |
| MutationTaster_pred          | Disease causing     | Disease causing automatic | Disease causing     |
| MutationAssessor_pred        | Low                 | High                | Medium              |
| Fathmm-MKL                   | Deleterious         | Deleterious         | Deleterious         |
| GERP++_RS                    | 5.73                | 4.97                | 2.87                |
| SiPhy_29way_logOdds          | 16.314              | 16.24               | 2.683               |
| Number of software predict deleterious | 4                  | 7                   | 4                   |
| Ration                       | 0.57                | 1                   | 0.57                |

SIFT: Sorting Intolerant From Tolerant; MKL: Multiple Kernel Learning; GERP: Genomic Evolutionary Rate Profiling; RS: Reference SNP Cluster ID

### Supplementary Table 3: Allele frequency in public population database

| Allele frequencies in public population database | p.I148T | p.H949Y | p.L997F |
|--------------------------------------------------|---------|---------|---------|
| avsn147 ID                                       | rs35516286 | rs121909035 | rs1800111 |
| 1000G                                            | 0.0014  | 0       | 0.0018  |
| Esp6500                                          | 0.0005  | 0       | 0.0015  |
| Exac03                                          | 0.0019  | 0       | 0.0021  |
| GnomAD                                          | 0.0018  | 0       | 0.0023  |

ClinVar interpretation: VCV000053949: CF, CBAVD from CFTR mutation | Pathogenic | VCV000007229.22: pathogenic

CF: cystic fibrosis; CFTR: cystic fibrosis transmembrane conductance regulator; CBAVD: congenital bilateral aplasia of vas deferens